Impact of adaptive intensity-modulated radiotherapy on the neutrophil-to-lymphocyte ratio in patients with nasopharyngeal carcinoma

Ning Han, Xintong Lyu, Guang Li and Qiao Qiao*

Abstract

Purpose: Nutritional status and haematological parameters are related to the prognosis of patients treated with radiotherapy, but the correlation between adaptive radiotherapy (ART) and haematological indicators has never been reported. This study explores the influence of ART on the change in haematological indicators and provides a theoretical basis for the use of ART in patients with nasopharyngeal carcinoma (NPC).

Patients and methods: We retrospectively analysed 122 patients with NPC from January 2014 to December 2015. Patients in two treatment groups were matched using the propensity score matching method at a ratio of 1:1. The data were analysed with the Kaplan–Meier method, log-rank tests, regression analyses and paired t tests.

Results: Significant differences were detected for changes in the neutrophil-to-lymphocyte ratio (ΔNLR), circulating lymphocyte count (ΔCLC), circulating platelet count (ΔCPC), and circulating neutrophil granulocyte count (ΔCNC) during radiotherapy (P = 0.002, P < 0.001, and P = 0.036, respectively) between the ART and non-ART groups. Differences in acute radiation injury to the parotid glands (PGs) (P < 0.001), skin (P < 0.001), and oral structures (P < 0.001), Δweight (kg) (P = 0.025), and Δweight (%) (P = 0.030) were also significant between the two groups. According to univariate and multivariate analyses, ART (R = 0.531, P = 0.004), skin-related side effects (R = 0.328, P = 0.020), and clinical stage (R = -0.689, P < 0.001) are influencing factors for the ΔNLR in patients. ART is also the influencing factor for the ΔCLC (R = 2.108, P < 0.001) and the only factor affecting the ΔCPC (R = 0.121, P = 0.035). Based on subgroup analyses, for stage T1–2N0–3 disease, ΔCLC was higher in patients in the ART group than in patients in the non-ART group (P < 0.001, P = 0.003, and P = 0.003).

Conclusion: ART ameliorates changes in haematological indexes (ΔNLR, ΔCLC, and ΔCPC) and reduces side effects to the skin and PGs and weight loss during radiotherapy in patients with NPC, and patients with stage T1–2 disease experience a greater benefit.

Keywords: Adaptive radiotherapy, Nutritional status, Haematological parameters, Side effects
Introduction

Intensity-modulated radiotherapy (IMRT) is the main treatment that facilitates the delivery of high radiation doses to the target and reduces the delivered dose to organs. IMRT shows excellent local control with few toxicities [1]. However, during IMRT, a significant shrinkage of the tumours and weight loss may occur in patients with nasopharyngeal carcinoma (NPC), and these changes can result in the delivery of decreased radiation doses to the tumour and increased doses to normal tissues [2]. Adaptive radiotherapy (ART) instantly corrects the target and dose based on repeat computed tomography (CT) imaging from each patient and re-planning during the course of IMRT to identify dosimetric changes and ensure the delivery of adequate doses to target volumes and safe doses to normal tissues; thus, ART can significantly alleviate late effects (injury to the mucosa and xerostomia) in patients [3, 4].

Studies show that 30–60% of patients with head and neck cancer (HNC) suffer from malnutrition caused by complex factors, including swallowing pain, anorexia and radiotherapy-induced symptoms, all of which impair the patient’s ability to eat, and many patients lose additional weight during and after treatment [5, 6]. These factors greatly aggravate malnutrition of patients during radiotherapy; additionally, poor nutritional status is significantly associated with poor prognosis in patients with head and neck squamous cell carcinoma [7–9]. ART can limit oral side effects and xerostomia resulting from radiation-induced damage mainly to the parotid glands (PGs) [4, 10], thereby enhancing the nutritional intake of patients and improving nutrition during and after radiotherapy.

With the rising incidence of HNC, the TNM staging system remains inadequate, and it is becoming increasingly important to find reliable prognostic parameters [11, 12]. Many studies have suggested that haematological parameters such as platelet counts and the neutrophil-to-lymphocyte ratio (NLR) can be used as indicators to predict the prognosis of cancer patients [8, 13–19]. Several pretherapeutic laboratory values, such as red cell count, have prognostic relevance for overall survival (OS) in patients with HNC [20].

Lou Y et al. found that compared with IMRT alone, IMRT re-planning facilitates improved local–regional recurrence-free survival (LRFS) in patients with stage T3/T4 NPC [21]. Several studies had previously proposed that nutritional status and haematological parameters during radiotherapy are associated with prognosis in patients with head and neck squamous cell carcinoma [7, 8, 13, 14]. In recent years, studies have suggested that nutritional status and haematological parameters are related to prognosis, but the correlation between ART and haematological indicators, such as the NLR, has never been reported. This study intends to explore the influence of ART on the change in haematological indicators and provide a theoretical basis for the use of ART in patients with NPC.

Material and methods

Patients

We included 122 newly diagnosed patients with histologically confirmed nonmetastatic NPC, who received radical radiotherapy with or without concurrent chemotherapy (CCT) in our hospital between January 2014 and December 2015 (Fig. 1). All patients were staged according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system [22]. This study was approved by the ethics committee of our hospital. Informed consent was obtained.

IMRT

All patients received IMRT with 6-megavoltage (MV) photons. The gross tumour target of the nasopharynx (GTVnx) and involved lymph nodes (GTVln) were outlined based on CT and magnetic resonance imaging (MRI) scans. The clinical target volume 1 (CTV1) included the GTVnx with a 5–10 mm margin and high risk structures. The clinical target volume 2 (CTV2) included regions of the nasopharyngeal cavity, maxillary sinus, pterygopalatine fossa, posterior ethmoid sinus, parapharyngeal space, skull base, anterior third of clivus, inferior sphenoid sinus, and cavernous sinus. The clinical lymph node volume (CTVln) included the upper neck lymphatic drainage regions. Organs at risk (OAR) were also outlined. The contoured critical structures included the brain stem, chiasm, optic nerves, spinal cord, eyes, lens, PGs, oral cavity, larynx, mandible, and temporomandibular joints. The prescribed doses were defined as follows: 66–70 Gy for GTVnx and GTVln; 60 Gy for CTV1; and 50 Gy for CTV2. Each dose was divided into 28–33 fractions. The dose limits for normal organs were set according to the Radiation Therapy Oncology Group (RTOG) protocol 0225 [23].

Art

All patients underwent weekly CT scanning. During each repeat CT scan, the patient maintained the same position, and the new CT scan was used to generate a new IMRT plan for the corresponding fractions of treatment. During the treatment, if re-planning was necessary, the target and OAR were re-contoured as required on the repeat CT scan and a new plan generated (Fig. 2). The aim of the new plan was to achieve comparable target volume coverage and OAR doses to the original plan.

CCT

CCT, which included cisplatin (75 mg/m2, days 1–3), was given to all patients.
Haematological parameters

Five parameters, namely, changes during radiotherapy in the NLR (ΔNLR), the circulating lymphocyte count (ΔCLC), the circulating platelet count (ΔCPC), the circulating neutrophil granulocyte count (ΔCNC), and the haemoglobin count (ΔHB), were analysed. The ΔNLR during radiotherapy is the result of subtraction of the count before radiotherapy (NLR1) from the count after radiotherapy (NLR2) divided by the count before radiotherapy (NLR1):

\[ \Delta \text{NLR} = \frac{\text{NLR}_2 - \text{NLR}_1}{\text{NLR}_1}. \]

The ΔCLC during radiotherapy is the result of subtraction of the CLC before radiotherapy (CLC1) from the CLC after radiotherapy (CLC2) divided by the CLC before radiotherapy (CLC1):

\[ \Delta \text{CLC} = \frac{\text{CLC}_2 - \text{CLC}_1}{\text{CLC}_1}. \]

The ΔCNC during radiotherapy is the result of subtraction of the CNC before radiotherapy (CNC1) from the CNC after radiotherapy (CNC2) divided by the CNC before radiotherapy (CNC1):

\[ \Delta \text{CNC} = \frac{\text{CNC}_2 - \text{CNC}_1}{\text{CNC}_1}. \]

The ΔCPC during radiotherapy is the result of subtraction of the CPC before radiotherapy (CPC1) from the CPC after radiotherapy (CPC2) divided by the CPC before radiotherapy (CPC1):

\[ \Delta \text{CPC} = \frac{\text{CPC}_2 - \text{CPC}_1}{\text{CPC}_1}. \]
The ΔHB during radiotherapy is the result of the subtraction of HB before radiotherapy (HB1) from HB after radiotherapy (HB2) divided by HB before radiotherapy (HB1): \( \Delta HB = (HB2 - HB1)/HB1 \).

Follow-up
All patients were evaluated weekly during radiotherapy and examined in follow-up appointments that were scheduled up to 1 month after the completion of radiotherapy and then every 3 months in years 1–2, every 6 months in years 3–5, and annually thereafter. Each follow-up included a flexible fibreoptic endoscopy, abdominal ultrasound, chest X-ray and basic serum chemistry. Either CT or MRI of the head and neck was also performed after the completion of IMRT and every 6 months thereafter.

Statistics
Propensity score matching was used to divide the patients into two groups (IMRT and ART+IMRT). A one-to-one matching without replacement was performed using a 0.5 caliper width. The \( \chi^2 \) test and paired t test were used to test the baseline balance between the two groups. The relationship between the change in haematological parameters and treatment-related factors was analysed by Pearson’s correlation. Variables with \( P < 0.05 \) were included in a multivariate analysis, performed by regression analysis. Subgroup analyses were performed using paired t tests. The rates of LRFS, distant metastasis-free survival (DMFS), progression-free survival (PFS) and OS were estimated with the Kaplan–Meier method and compared with the log-rank test. All data were analysed using SPSS 22.0 software package (IBM Corporation, Armonk, NY, USA).

Results
Patients and characteristics
After matching, 55 and 67 patients were treated with ART+IMRT and IMRT, respectively. Among them, 50 patients treated with ART+IMRT and 50 patients with IMRT were included in the analysis. All subsequent analyses were based on the propensity-matched cohort. The characteristics of patients after propensity score matching are shown in Table 1.

Changes in haematological parameters in different radiotherapy modes
There were no significant differences in the pretreatment NLR, CLC, CPC, or CNC between the two groups, while the differences in the ΔNLR (\( P = 0.002 \)), ΔCLC (\( P < 0.001 \)), and ΔCPC (\( P = 0.036 \)) were statistically significant. Differences in acute radiation injury classification of the PGs (\( P < 0.001 \)), skin (\( P < 0.001 \)) and oral structures (\( P < 0.001 \)) were also significant in both groups and are shown in Table 2. We also compared Δweight (kg) and Δweight (%) for the two groups during radiotherapy and observed a significant difference (\( P = 0.025 \) and \( P = 0.030 \), respectively).

Side effects were significantly different between the two groups; however a previous study had concluded that the mean dose (Dmean) to the PGs is related to xerostomia during the course of IMRT and that ART can decrease the Dmean to the PGs [10]. Therefore, we compared Dmean and dose to 50% of the volume (D50) for the PGs and Dmean, D50, and the maximum dose for the skin. Additionally, we excluded 19 patients with missing weekly CT data in the IMRT group, and 19 matched patients in the ART+IMRT group were also excluded. Moreover, 1 patient without weekly CT data in

| Table 1 | Patient characteristics and treatment details after propensity score matching |
|---------|--------------------------|
| Characteristics | ART+IMRT (n = 50) | IMRT (n = 50) | P |
| Age (years) | 54 (16~72) | 55 (22~73) | 0.865 |
| Gender | | | 0.500 |
| Male | 33 (66%) | 34 (68%) | |
| Female | 17 (34%) | 16 (32%) | |
| History of smoking | | | 0.500 |
| Yes | 22 (44%) | 23 (46%) | |
| No | 28 (56%) | 27 (54%) | |
| History of drinking | | | 0.795 |
| Yes | 8 (16%) | 10 (20%) | |
| No | 42 (84%) | 40 (80%) | |
| Family history | | | 0.795 |
| Yes | 10 (20%) | 8 (16%) | |
| No | 40 (80%) | 42 (84%) | |
| T stage | | | 1 |
| T1 | 1 (2%) | 1 (2%) | |
| T2 | 29 (58%) | 29 (58%) | |
| T3 | 14 (28%) | 14 (28%) | |
| T4 | 6 (12%) | 6 (12%) | |
| N stage | | | 1 |
| N0 | 7 (14%) | 7 (14%) | |
| N1 | 11 (22%) | 11 (22%) | |
| N2 | 27 (54%) | 27 (54%) | |
| N3 | 5 (10%) | 5 (10%) | |
| Clinical stage | | | 1 |
| II | 3 (6%) | 3 (6%) | |
| III | 40 (80%) | 40 (80%) | |
| IV | 7 (14%) | 7 (14%) | |
| CCT | 50 (100%) | 50 (100%) | |
the ART+IMRT group was excluded, and the matched patient in the IMRT group was also excluded. Hence, the new IMRT (IMRT new) and the new ART+IMRT (ART+IMRT new) groups were created, with 30 patients in each group. By comparison, differences in the Dmean, and D50 for the PGs and D50 for the skin were significant. For ipsilateral PGs, the difference in D50 and Dmean between the two groups was 1.28 Gy ($P = 0.021$) and 1.12 Gy ($P = 0.038$), respectively. For contralateral PGs, the difference in D50 and Dmean between the two groups was 1.28 Gy ($P = 0.021$) and 0.92 Gy ($P = 0.034$), respectively. For the skin, the difference in D50 between the two groups was 11.85 Gy ($P < 0.001$) (Table 3).

### Changes in haematological parameters and related factors
Relevant variables were included in the correlation analysis and regression analysis. The ΔNLR, ΔCLC, and ΔCPC were normally distributed. In univariate analyses, clinical stage ($R = -0.719$, $P = 0.001$), ART ($R = -0.721$, $P < 0.001$) and acute radiation injury grade of the skin ($R = 0.536$, $P = 0.001$) were significantly associated with the ΔNLR. Additionally, ART was significantly associated with the ΔCLC ($R = 2.150$, $P < 0.001$), and ART ($R = 0.121$, $P = 0.035$) was the only significantly correlated factor with the ΔCPC (Table 4).

According to the results of univariable analyses, ART, acute radiation injury grade of the skin, and clinical stage were included in a multivariate analysis. Based on the results of the multivariate analysis, ART, acute radiation injury grade of the skin, and clinical stage were the influencing factors of the ΔNLR in patients ($R = 0.531$, $P = 0.004$; $R = 0.328$, $P = 0.020$; and $R = -0.689$, $P < 0.001$, respectively). ART was further included in a multivariate regression analysis of ΔCLC. Because acute radiation injury grade of the skin had a $P$ value of 0.053, close to 0.05, this factor was also included in the multivariate analysis. After calculation, the side effect to the skin was excluded, and ART was identified as the influencing factor of the ΔCLC ($R = 2.108$, $P < 0.001$). ART was also the only factor that affected the ΔCPC ($R = 0.121$, $P = 0.035$) (Table 5).

### Subgroup analysis
To identify patients who benefited the most from ART, we performed subgroup analyses according to the T stage (T1–2 and T3–4) and N stage (N0–2 and N3).

### Table 2 Comparison of radiotherapy-related variables between the two groups

| Characteristics | ART+IMRT (n = 50) | IMRT (n = 50) | P     |
|-----------------|-------------------|--------------|-------|
| Pre-NLR         | 2.00 ± 1.78       | 2.81 ± 2.54  | 0.076 |
| Pre-CLC (10^9/L)| 1.54 ± 0.60       | 1.66 ± 0.76  | 0.381 |
| Pre-CNC (10^9/L)| 4.12 ± 1.65       | 4.16 ± 1.87  | 0.907 |
| Pre-HB (g/L)    | 143.26 ± 15.46    | 138.92 ± 44.15 | 0.534 |
| ΔNLR (%)        | −1.80 ± 114.02    | 70.34 ± 49.40 | <0.001* |
| ΔCLC (%)        | −126.33 ± 119.97  | −341.36 ± 320.99 | <0.001* |
| ΔCNC (%)        | −14.43 ± 65.43    | −30.57 ± 89.83 | 0.288 |
| ΔCPC (%)        | −4.52 ± 23.15     | −16.62 ± 32.07 | 0.036* |
| ΔHCG (%)        | 45.68 ± 11.19     | 45.7 ± 26.88  | 0.303 |
| ΔWeight (Kg)    | −3.76 ± 3.13      | −5.04 ± 2.09  | 0.025* |
| ΔWeight (%)     | −7.99 ± 3.60      | −5.98 ± 4.87  | 0.030* |

### Table 3 Dosimetric changes in the OAR

| OARs            | ART+IMRT new No.Gy | IMRT new No.Gy | P   |
|-----------------|---------------------|----------------|-----|
| PG ips D50      | 26.11 ± 6.12        | 27.39 ± 7.19   | 0.021* |
| Dmean           | 28.68 ± 5.99        | 29.80 ± 7.12   | 0.038* |
| PG con D50      | 24.69 ± 3.92        | 25.95 ± 4.20   | 0.009* |
| Dmean           | 27.10 ± 4.01        | 28.02 ± 4.38   | 0.034* |
| Skin D50        | 3.03 ± 3.18         | 14.88 ± 6.65   | <0.001* |
| Dmean           | 21.22 ± 2.22        | 18.52 ± 4.21   | 0.491 |
| Dmax            | 70.64 ± 5.52        | 71.29 ± 5.41   | 0.076 |

Abbreviations: OAR organs at risk, PGs parotid glands, Dmean mean dose, D50 dose to 50% of the volume, IMRT new the new IMRT, ART+IMRT new, the new ART+IMRT

$P \leq 0.05$
The clinical stage was related to the ΔNLR during radiotherapy and was identified as an independent prognostic factor of the ΔNLR. However, there was not a wide distribution among clinical stages, and TNM staging is closely related to the clinical stage. Therefore, we performed subgroup analysis according to the TNM classification.

For patients with stage T1–4 N0–3 disease, the ΔNLR was higher in patients treated with IMRT than in patients treated with ART+IMRT (P = 0.018, P = 0.032, P = 0.029, and P = 0.004, respectively). For patients with T1–2 N0–3 disease, the ΔCLC was higher in patients treated with ART+IMRT than in patients treated with IMRT (P < 0.001, P = 0.003, and P = 0.003, respectively). These differences were significant (Table 6).

### Survival

The median follow-up time in the IMRT group was 33 months (12.9–45.4 months), and that in the ART+IMRT group was 33.1 months (7.1–46.8 months). The differences in OS(Fig. 3a), PFS(Fig. 3b), LRFS(Fig. 3c), and DMFS(Fig. 3d) between these two groups were not statistically significant (P = 0.750, P = 0.659, P = 0.685, and P = 0.764, respectively) (Fig. 3). Local recurrence was found in 3 (6%) patients in the ART+IMRT group and in 9 (18%) patients in the IMRT group, with fewer local recurrences in the ART+IMRT group than in the IMRT group.

### Discussion

In this study, we found that ART reduces side effects during radiotherapy in patients with NPC. We compared the acute radiation injury responses of the PGs, skin and oral structures in the last week of radiotherapy, and the differences were obvious. The differences in the ART+IMRT group was significantly less pronounced than that in the IMRT group. The acute radiation response grade for the PGs was ≥2 after the treatment in 50 patients receiving IMRT, while this was true for 37 patients in the ART+IMRT group; likewise, the acute radiation response grade for the skin was ≥2 for 32 patients in the IMRT group and 10 patients in the ART+IMRT group. The reason was that ART decreased the radiation dose to normal tissues [3, 4]. The PGs are the most vulnerable organ during radiotherapy, regardless of volume or displacement, and the dose to the PGs results in the risk of xerostomia. Excess radiation dose to the PGs increases the risk of xerostomia, leading to a deterioration in the quality of life (QOL) [10]. Severe side effects, such as xerostomia and difficulty in swallowing can lead to malnutrition, which is associated with poor prognosis [10, 24]. Joel Castelli et al. noted that anatomical changes during IMRT were the main cause of overdose to the PGs [10]. The average volume of the PGs decreased by 28% during radiotherapy, and the weekly re-planning could account for the changes in the volume of the PGs in real time. The Dmean for the PGs
| Characteristics      | ΔNLR       |          |          | ΔCLC       |          |          | ΔCPC       |          |          |
|---------------------|------------|----------|----------|------------|----------|----------|------------|----------|----------|
|                     | Regression | SD       | Standard regression coefficient | T         | P        | Regression | SD       | Standard regression coefficient | T         | P        |
| ART                 | -0.531     | 0.181    | -0.280   | -2.933     | 0.004*   | 2.108     | 0.549      | 0.398     | 3.842     | <0.001*   | 0.121     | 0.067     | 0.211     | 2.141     | 0.035*   |
| Acute injury of skin| 0.328      | 0.139    | 0.226    | 2.366      | 0.020*   | -0.073    | 0.419      | -0.018    | -0.174    | 0.862     | -        | -        | -        | -        | -        |
| Clinical stage      | -0.689     | 0.185    | -0.320   | -3.727     | <0.001*  | -        | -         | -         | -        | -        | -        | -        | -        | -        |

*P ≤ 0.05

Abbreviations: ART adaptive radiotherapy, NLR neutrophil-to-lymphocyte ratio, CLC circulating lymphocyte count, CPC circulating platelet count
decreased by an average of 5 Gy, and the risk of xerostomia decreased by 11% [10]. The Dmean to the PGs is associated with the volume of PGs during radiotherapy [25–30], and there was a difference between the delivered dose and the planned dose to the PGs during radiotherapy. Brouwer also demonstrated that the Dmean to the PGs in patients with HNC significantly increased during radiotherapy, and ART reduced the Dmean to the PGs, thus alleviating the symptoms of xerostomia [4]. Deng et al. noted that patients with NPC who received IMRT experienced significant anatomical changes during the course of treatment, and ART was necessary to maintain optimal doses to targets and OAR. Patients with NPC who were subjected to re-planning at cycles 5 and 15 were compared with patients who only received IMRT. The planning target volume in the ART group were significantly improved. Compared with those in the IMRT group, the Dmean to the PGs in the ART+IMRT group decreased by 1.27 ± 1.05 Gy, the V50 to the PGs decreased by 4.12 ± 3.58%, and the V55 for the skin decreased by 0.91 ± 1.83% [31].

Myelosuppression is a common side effect of radiotherapy. When myelosuppression occurs, haematopoietic stem cells cannot produce enough normal blood cells, which leads to complications such as anaemia, infection and bleeding, and these complications seriously affect the survival of patients. Moreover, as inflammation plays an important role in tumour development [32], many studies have suggested that inflammation-related factors (such as the NLR, lymphocyte count, and neutrophil count) in the blood can predict the prognosis of patients, [32–39] and these parameters can be evaluated by conventional examinations. Several studies have shown that a decrease in lymphocyte count in the peripheral blood of patients with NPC is associated with poor OS and PFS [33, 34, 36, 37], and that the neutrophil count is related to OS, DSS, and DMFS [33, 38]. The NLR was also thought to be associated with prognosis in many types of cancers [39–41], and a higher NLR is related to poor prognosis [42–47]. A meta-analysis by Yukinori Take-naka demonstrated that elevated NLR was associated with poor OS, DSS, PFS, and DMFS [48]. In our study, 12 (24%) patients treated with ART+IMRT had a lower NLR after treatment than that before; additionally, 41 (81%) patients experienced a decrease in the CLC, 36 (72%) patients experienced a decrease in the CNC, and 31 (62%) patients experienced a decrease in the CPC after treatment. For the IMRT group, these number were 3 (6%), 48 (96%), 24 (48%), and 38 (76%), respectively.

### Table 6 Comparison of the ΔNLR, ΔCLC, and ΔCPC in different subgroups according to TNM stages

| Characteristics | ΔNLR(%) | ΔCLC(%) | ΔCPC(%) |
|-----------------|---------|---------|---------|
| T stage         |         |         |         |
| 1–2(n = 30)     | 15.61 ± 65.69 | 59.03 ± 58.52 | 0.018* | −117.93 ± 88.14 | −406.47 ± 350.15 | < 0.001* | −6.80 ± 20.87 | −19.07 ± 34.61 | 0.107 |
| 3–4(n = 20)     | −27.92 ± 157.78 | 57.65 ± 34.57 | 0.032* | −138.93 ± 155.13 | −243.70 ± 240.36 | 0.095 | −1.1 ± 26.93 | −12.96 ± 29.24 | 0.199 |
| N stage         |         |         |         |
| 0–1(n = 18)     | 2.17 ± 130.78 | 76.54 ± 12.69 | 0.029* | −109.18 ± 107.03 | −312.87 ± 219.52 | 0.003* | −6.21 ± 24.70 | −18.57 ± 25.47 | 0.171 |
| 2–3(n = 32)     | −4.03 ± 107.59 | 66.85 ± 61.10 | 0.004* | −135.98 ± 129.10 | −357.39 ± 372.84 | 0.003* | −3.58 ± 22.97 | −15.53 ± 36.05 | 0.117 |

Abbreviations: ART adaptive radiotherapy, IMRT Intensity-modulated radiotherapy, NLR neutrophil-to-lymphocyte ratio, CLC circulating lymphocyte count; CPC, circulating platelet count

*P < 0.05

**Fig. 3** ART flow chart. Weekly CT scans were performed during the treatment. Doses were calculated for each weekly fraction. Abbreviations: IMRT, Intensity-modulated radiotherapy; ART, adaptive radiotherapy; NPC, nasopharyngeal carcinoma; CT, computed tomography
Patients in the ART and IMRT groups demonstrated significant differences in the ΔANLR (P < 0.001), ΔCLC (P < 0.001), ΔCNC (P = 0.045), and ΔCPC (P = 0.03). This finding supports the changes in haematological parameters during radiotherapy in patients. ART can ameliorate the decrease in haematological parameters during radiotherapy and mitigate myelosuppression after radiotherapy.

Furthermore, correlation analysis and regression analysis showed that ART was an independent factor influencing haematological parameters (ΔANLR, ΔCLC, and ΔCPC). A study of cervical cancer patients by Emily et al. suggested that pre-treatment total lymphocyte count (TLC) ≥1000 cells/mm³ and post-treatment TLC > 500 cells/mm³ indicated a 77% (hazard ratio (HR): 0.23; 95% confidence interval (CI): 0.05–1.03; P = 0.053) and 58% decrease in the risk of death (HR: 0.42; 95% CI: 0.12–1.46; P = 0.17), respectively [8]. Unfortunately, no such studies have recently been conducted for HNC.

A retrospective study in 2016 suggested that ART can improve the prognosis of patients with NPC. The study followed 132 NPC patients (66 receiving ART and 66 receiving IMRT), and the 5-year LRFS rate was higher in the IMRT re-planning group than in the IMRT only group (96.7 vs. 88.1%, P = 0.022). Distant metastasis remains the main pattern of treatment failure. A total of 21.2% patients in the IMRT re-planning group and 28.8% patients in the IMRT only group had distant metastasis [21]. Two previous studies have also suggested that ART improves clinical outcomes in patients with HNC, including improvements in local control and reductions in late side effects [3, 21]. However, based on our follow-up data, the differences in OS, PFS, DMFS, and LRFS were not statistically significant, although 3 (6%) patients in the ART+IMRT group 9 (18%) patients in the IMRT group experienced local recurrence. During the course of radiotherapy, most patients experienced anatominical changes, such as tumour shrinkage and weight loss, resulting in an insufficient dose to the target area [2], which greatly improved the LRFS rate of patients. ART can alleviate these anatomical changes to maintain a satisfactory dose to the target volumes [21].

Although studies have shown that patients with the same TNM stage may have different clinical outcomes [49–51], TNM stages remain the standard for predicting prognosis and stratification of patients in studies. In our study, patients were separated according to their TNM stage. The results showed that the change in haematological parameters of patients with stage T1–2 disease was significantly better than that of patients with stage T3–4 disease. Notably, the number of patients in this study was limited.

**Conclusion**

Our study compared changes in side effects, haematologic parameters and weight during radiotherapy between patients receiving ART+IMRT and IMRT alone. We found that ART had an effect on the side effects and the change in haematologic parameters during radiotherapy, and patients with T1–2 disease experienced a greater benefit. According to the follow-up, the differences in OS, PFS, LRFS and DMFS were not statistically significant, but the number of local recurrences in the IMRT group was higher than that in the ART+IMRT group. Nevertheless, these results are preliminary and need to be validated.

**Additional file**

- **Additional file 1:** Patient characteristics and radiotherapy-related variables between the two groups. (XLSX 23 kb)

**Acknowledgements**

Not applicable.

**Authors’ contributions**

NH, QQ have made substantial contributions to conception and design; NH, XTL, and GL have made substantial contributions to acquisition of data, or analysis and interpretation of data; NH, XTL and QQ have been involved in drafting the manuscript or revising it critically for important intellectual content; All authors have given final approval of the version to be published; All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Availability of data and materials**

Data used in this study can be found in the Additional file 1: Table S1.

**Ethics approval and consent to participate**

This study was approved by the Ethics Committee of the First Hospital of China medical University. Informed consent was obtained.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Received**

30 June 2019 **Accepted**

28 July 2019

**Published online**

22 August 2019

**References**

1. Xiao W, Huang S, Han F, et al. Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer. 2011;117(9): 1874–83.
2. Cheng H, Wu V, Ngn R, et al. A prospective study on volumetric and dosimetric changes during intensity-modulated radiotherapy for nasopharyngeal carcinoma patients. Radiother Oncol. 2012;104(3):317–23.
3. Zhao L, Wan Q, Zhou Y, Deng X, Xie C, Wu S. The role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinoma. Radiother Oncol. 2011;98(1):23–7.
4. Brouwer C, Steenbakkers R, van der Schaaf A, et al. Selection of head and neck cancer patients for adaptive radiotherapy to decrease xerostomia. Radiother Oncol. 2016;120(1):36–40.
11. Dahlstrom K, Calzada G, Hanby J, et al. An evolution in demographics, weight loss and its correlation with disease-free survival in patients with oral squamous cell carcinomas. Nutr Cancer. 2013;65(3):417–23.

12. Rios Velazquez E, Hoebers F, Aerts H, et al. Externally validated HPV-based prognostic nomogram for oropharyngeal carcinoma patients yields more accurate predictions than TNM staging. Radiother Oncol. 2014;113(3):324–30.

16. Zhu M, Feng M, He F, Han B, et al. Pretreatment neutrophil-lymphocyte and neutrophil-monocyte ratios predict clinical outcome and prognosis for nasopharyngeal cancer patients receiving intensity-modulated radiotherapy. Onco Targets Ther. 2017;10:2751–60.

17. Wu CC, Li SH, Lu HI, Lo CM, Wang YM, Chou SY, Chen YH. Inflammation-based prognostic scores predict the prognosis of locally advanced cervical esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy: a propensity score-matched analysis. PeerJ. 2018;6:e5655 (undefined).

27. Sanguineti G, Riccetti F, Thomas O, Wu B, McNutt T. Pattern and predictors of volumetric change of parotid glands during intensity modulated radiotherapy. Br J Radiol. 2013;86(1029):20130363.

Sanguineti G, Riccetti F, Wu B, McNutt T, Fiorino C. Parotid gland shrinkage during IMRT predicts the time to xerostomia resolution. Radiat Oncol. 2015;10:19.

Vásquez Osorio E, Hoogeman M, Al-Mamgani A, Teguh D, Devendran P, Heijmen B. Local anatomic changes in parotid and submandibular glands during radiotherapy for oropharynx cancer and correlation with dose, studied in detail with nonrigid registration. Int J Radiat Oncol Biol Phys. 2008;70(3):875–82.

28. Wang X, Lu J, Xiong X, et al. Anatomical and dosimetric changes during the treatment course of intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma. Med Dosim. 2010;35(2):151–7.

29. Vásquez Osorio E, Hoogeman M, Al-Mamgani A, Teguh D, Devendran P, Heijmen B. Local anatomic changes in parotid and submandibular glands during radiotherapy for oropharynx cancer and correlation with dose, studied in detail with nonrigid registration. Int J Radiat Oncol Biol Phys. 2008;70(3):875–82.

30. Wang X, Lu J, Xiong X, et al. Anatomical and dosimetric changes during the treatment course of intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma. Med Dosim. 2010;35(2):151–7.

31. Deng S, Liu X, Lu H, et al. Three-phase adaptive radiation therapy for patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: Dosimetric analysis. Technol Cancer Res Treat. 2017;153304617709396.

32. He J, Shen G, Ren Z, et al. Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma. Head Neck. 2012;34(2):1769–76.

33. Jin Y, Ye X, He C, Zhang B, Zhang Y. Pretreatment neutrophil-to-lymphocyte ratio as predictor of survival for patients with metastatic nasopharyngeal carcinoma. Head Neck. 2015;37(7):1669–75.

34. Su L, Zhang M, Zhang W, Cai C, Hong J. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(11):e3634.

35. Jiang R, Cai X, Yang Z, et al. Elevated peripheral blood lymphocyte-to-monocyte ratio predicts a favorable prognosis in the patients with metastatic nasopharyngeal carcinoma. Chin J Cancer. 2015;34(6):237–46.

36. Li J, Jiang R, Liu W, et al. A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma. PLoS One. 2013;8(12):e83869.

37. Luo X, He W, Huang H, et al. Design of a prognostic score model for nasopharyngeal carcinoma. Head Neck. 2015;37(5):624–9.

38. Ke L, Xiang Y, Xia W, et al. A prognostic model predicts the risk of distant metastasis and death for patients with nasopharyngeal carcinoma based on pretreatment interleukin 6 and clinical stage. Clin Immunol. 2016;164(4):51–60.

39. Templeton A, McMamara M, Seruaga B, et al. Prognostic value of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):djtu124.

40. Sunakawa Y, Yang D, Cao S, et al. Immune-related genes to dominate neutrophil-lymphocyte ratio (NLR) associated with survival of Cetuximab treatment in metastatic colorectal Cancer. Clin Colorectal Cancer. 2018;17(4):e741–e749.

41. Mittl C, Guney I, Paydas S, et al. Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC). Int J Clin Oncol. 2018;23(2):168–78.

42. Ye S, Bai L. Comparison and validation of the value of preoperative inflammation marker-based prognostic scores in resectable pancreatic ductal adenocarcinoma. Cancer management and research. 2018;10:5905–17 (undefined).

43. García-Ortega D, Álvarez-Cano A, Sánchez-Llamas L, et al. Neutrophil/lymphocyte ratio is associated with survival in syncyial sarcoma. Surg Oncol. 2018;27(3):551–5.

44. De Felice F, Tombolini M, Abate G, et al. Prognostic significance of the neutrophil/lymphocyte ratio in patients with non-human papilloma virus-related oropharyngeal Cancer: a retrospective cohort study. Oncology. 2018–6.

45. He W, Hu W, Kong P, et al. Systemic neutrophil lymphocyte ratio and mismatch repair status in colorectal cancer patients: correlation and prognostic value. J Cancer. 2018;9(13):3993–100.

46. Nishijima T, Deal A, Lund J, Nyrop K, Mims H, Sanfilippo. Inflammatory markers and overall survival in older adults with cancer. J Geriatr Oncol. 2018;10(2):279–84.

47. Thio Q, Goudraan W, Janssen S, et al. Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases. Br J Cancer. 2018;119(6):37–43.

48. Takenaka Y, Karama T, Oya R, et al. Prognostic role of neutrophil-to-lymphocyte ratio in nasopharyngeal carcinoma: a meta-analysis. PLoS One. 2017;12(7):e0181478.

49. Li Q, Gao J, Tao Y, et al. Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma. Chin J Cancer. 2012;31(4):197–206.
50. Lee A, Ng W, Chan L, et al. The strength/weakness of the AJCC/UICC staging system (7th edition) for nasopharyngeal cancer and suggestions for future improvement. Oral Oncol. 2012;48(10):1007–13.
51. Li X, Chang H, Xu B, et al. An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma: an analysis of a prospective study. Cancer Med. 2017;6(1):310–9.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.